Spyre Therapeutics, Inc.
SYRE
$23.78
-$0.68-2.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.46% | -2.09% | 10.90% | -72.11% | 82.11% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -114.01% | -63.29% | -75.60% | 117.34% | -97.04% |
| Change in Net Operating Assets | 68.99% | -116.35% | 679.60% | 230.18% | -588.21% |
| Cash from Operations | 25.20% | -43.63% | -19.86% | 14.96% | -274.02% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 159.74% | 99.94% | -383.51% | 143.78% | -3,808.25% |
| Cash from Investing | 165.55% | 99.94% | -383.51% | 143.78% | -1,882.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 47.68% | -92.37% | 166.31% | 12,355.24% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | 98.26% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 85.31% | 94.31% | -- | -- |
| Cash from Financing | 103.06% | -99.93% | 37.89% | 201.99% | -99.83% |
| Foreign Exchange rate Adjustments | -- | -- | -183.33% | 194.12% | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.18% | -205.88% | -81.66% | 118.04% | -191.15% |